Facebook
X
LinkedIn
ForwardWe’re AML/ALL in this Together: Emerging Therapy Combinations in Acute Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia: Mt. Sinai Hospital
At the Hospital or Via Zoom
Target Audience
All pharmacists
Learning Objectives
At the completion of this activity, the participant will be able to:
Describe the epidemiology and pathophysiology of acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL), highlighting key risk factors
Review the landmark clinical trials that have paved the way for the approval of new emerging therapies in acute leukemia
Discuss current clinical guidelines and treatment recommendations for managing newly diagnosed AML and Ph+ ALL, emphasizing the new treatment paradigms
Summarize future trends and emerging therapies in acute leukemia treatment, including novel treatment regimens and upcoming clinical trials
Chan Tae Park, PharmD.
Chan Tae (CT) is a current PGY1 pharmacy resident at The Mount Sinai Hospital. He graduated from Northeastern University and has had a passion for hematology/oncology, having had experience and rotations at Dana Farber Cancer Institute, Boston Medical Center, and at Mount Sinai. He has recently committed to PGY2 in hematology/oncology at Mount Sinai this July and is excited to pursue a career as a clinical oncology pharmacist.
UAN# 0042-0000-26-024-L01-P
Available Credit
- 1.00 ACPEThe Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.